-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Image: Schematic 3D model of Toxoplasma gondii in the host cell
Source: University of Nottingham
The research was led by researchers from the University of Nottingham and Shanxi Agricultural University and was published in the Journal for ImmunoTherapy Cancer
In order to overcome certain cancers, prevent tumor deterioration, prolong the lives of patients, and improve the therapeutic effect of certain types of tumors is essential
The scientists who led the study believe that this discovery may have broader therapeutic implications for a variety of cancers
The team successfully "tamed" Toxoplasma gondii, a single-celled protozoan that can infect various warm-blooded animals.
Toxoplasma gondii must live in the host's cells and secrete many proteins to fight the host's immune defense and promote its own invasion and colonization of host cells
Researchers have shown that direct injection of this mutant parasite into a solid tumor can trigger an inflammatory response in the injected tumor, or even in a tumor at a remote location in the mouse
This dual treatment significantly prolonged the survival time of mice and reduced tumor growth in mouse models of melanoma, Lewis lung cancer, and colon adenocarcinoma
Dr.
"These findings are of great significance and are related to future tumor treatments
DOI
10.
Article title
Synergy between Toxoplasma gondii type I ΔGRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors
